- Conditions
- Contraception, Change in Bone Mineral Density
- Interventions
- Drospirenone
- Drug
- Lead sponsor
- Insud Pharma
- Industry
- Eligibility
- 13 Years to 45 Years · Female only
- Enrollment
- 1,542 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 46
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Contraception
- Interventions
- LF111 (drospirenone)
- Drug
- Lead sponsor
- Laboratories Leon Farma, S.A.
- Industry
- Eligibility
- 15 Years and older · Female only
- Enrollment
- 1,552 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Anaheim, California • Costa Mesa, California + 32 more
- Conditions
- Change in Bone Mineral Density, Bone Loss
- Interventions
- drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
- Drug
- Lead sponsor
- Insud Pharma
- Industry
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 1,536 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more
- Conditions
- Residual Drug Amount of EE and LNG
- Interventions
- Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System
- Drug
- Lead sponsor
- Insud Pharma
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Contraception
- Interventions
- LPRI424 (dienogest/ethinylestradiol)
- Drug
- Lead sponsor
- Insud Pharma
- Industry
- Eligibility
- 13 Years to 45 Years · Female only
- Enrollment
- 1,034 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Savannah, Georgia
- Conditions
- Vaginosis, Bacterial
- Interventions
- Metronidazole Gel
- Drug
- Lead sponsor
- Insud Pharma
- Industry
- Eligibility
- 12 Years to 17 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- Long Beach, California • Paramount, California • Bardstown, Kentucky + 5 more